10-K Decoder · All companies

BioCryst Pharmaceuticals, Inc.

BCRX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$875M$451M+94.1%
Operating income$341M−$2.54M
Net income$264M−$88.9M

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 4, 2026

$Q3 2026Year earlierChange
Revenue$180M$159M+13.1%
Operating income$53.3M$29.6M+80.1%
Net income$37.9M$12.9M+194%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was BioCryst's revenue in FY2025?
$875M in FY2025 (Fiscal year ended Dec 31, 2025), +94.1% vs $451M a year earlier, per its 10-K filed Feb 2026.
Was BioCryst profitable in FY2025?
Yes: net income was $264M and operating income $341M in FY2025.
What was BioCryst's revenue in Q3 2026?
$180M (+13.1% vs a year earlier), per its Form 10-Q filed Nov 4, 2026.